Ovation's Epilepsy Drug Granted Orphan Drug Designation
Posted on: Friday, 4 January 2008, 03:00 CST
The FDA has granted orphan drug designation for Ovation Pharmaceuticals's clobazam as an adjunctive treatment for Lennox-Gastaut syndrome, one of the most severe forms of childhood epilepsy that frequently persists into adulthood.
The FDA grants orphan drug designation to products that are intended to treat rare or 'orphaned' diseases or conditions such as Lennox-Gastaut syndrome (LGS).
Tim Cunniff, vice president, global regulatory affairs, pharmacovigilance and clinical quality assurance from Ovation, said: "LGS is a devastating and difficult to treat form of childhood epilepsy that often leads to some form of mental retardation and other behavioral problems over time. Clobazam is being developed to provide physicians with an additional treatment option for patients with LGS, for whom there are very few safe and effective treatments."
Source: Datamonitor
Related Articles
- LG Mobile Phones and Sprint Introduce Sleek, Sliding Handset
- LG Electronics Inc. Chooses Airbiquity Inc.'s aqLink Software Modem for Use in Telematics Products
- LG Electronics Deploys Mindspeed Comcerto VoIP Processor in W-CDMA Media Gateway
- Simplify Your Life With the New Handset From LG Mobile Phones and AT&T Wireless
- Siemens, LG Talks on Phone JV
- LG Mobile Phones and AT&T Wireless Offer Phones to Match Your Lifestyle With the Launch of Two Sleek New GSM Handsets
- Sprint and LG Mobile Phones Debut the 'Little Black Dress' of Wireless Handsets
- Silicon Image Technology Designed Directly Onto LCD Panel by Lg.Philips LCD
- LG Electronics Deploys Mindspeed Communications Convergence Processsor in CDMA2000 Wireless System
- LG Electronics Picks Tensilica's Xtensa Processor For the Digital Multimedia Broadcasting Project of the Korean Government
 |
 |
User Comments (0)
RSS Feeds